tiprankstipranks
Relmada Therapeutics (RLMD)
NASDAQ:RLMD
Holding RLMD?
Track your performance easily

Relmada Therapeutics (RLMD) Income Statement

302 Followers

Relmada Therapeutics Income Statement

Last quarter (Q3 2024), Relmada Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Relmada Therapeutics's net income was $-21.73M. See Relmada Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Jun 19
Total Revenue
------
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 91.35M$ 103.70M$ 161.25M$ 125.70M$ 60.84M$ 12.73M
Operating Income
$ -91.35M$ -103.70M$ -161.25M$ -125.70M$ -60.84M$ -12.73M
Net Non Operating Interest Income Expense
$ 4.40M$ 5.15M$ 2.66M$ 1.20M$ 1.40M$ -761.04K
Other Income Expense
$ -770.43K$ -241.16K$ 1.55M$ 1.25M$ 16.95K$ 3.77M
Pretax Income
$ -86.66M$ -98.79M$ -157.04M$ -125.75M$ -59.46M$ -17.32M
Tax Provision
$ 88.61M$ 88.61M$ 6.20M---
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -86.66M$ -98.79M$ -157.04M$ -125.75M$ -59.46M$ -17.32M
Basic EPS
$ -2.88$ -3.28$ -5.30$ -7.16$ -3.81-
Diluted EPS
$ -2.88$ -3.28$ -5.30$ -7.16$ -3.81$ -2.76
Basic Average Shares
$ 120.55M$ 30.10M$ 29.63M$ 17.55M$ 15.59M$ 6.31M
Diluted Average Shares
$ 120.55M$ 30.10M$ 29.63M-$ 15.59M$ 6.31M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 91.17M$ 103.70M$ 161.25M$ 125.70M$ 60.84M$ 12.73M
Net Income From Continuing And Discontinued Operation
$ -86.66M$ -98.79M$ -157.04M$ -125.75M$ -59.46M$ -17.32M
Normalized Income
$ -76.36M$ -78.05M-$ -99.34M--
Interest Expense
------
EBIT
$ -89.02M$ -103.70M$ -161.25M$ -125.70M$ -60.84M$ -16.56M
EBITDA
$ -89.02M$ -103.70M$ -161.25M$ -125.70M$ -60.83M$ -15.89M
Currency in USD

Relmada Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis